Digital Innovation in the Life Sciences Industry

The Life Sciences (LS) industry has historically been conservative when it comes to adopting technologies. Companies in this space face distinct challenges given their role in drug pricing and access to medicines, and the pandemic underscored this. Shifts to more data-driven approaches, greater collaborations, digital transformation, and the advancing CEO priorities are driving recent changes.

The UK is well placed to become the standard bearer for data-driven health research and innovation. It can lead the way in the use of data to enhance and expedite research and development of new healthcare treatments through to clinical and regulatory processes for the appraisal, approval and monitoring of such innovations.

Guest blog by Nigel Brokenshire, Head of Digital Healthcare UK&I at Bayer PLC

Connected devices can transform care delivery for patients and improve outcomes. Post-COVID, there is an immediate opportunity to make care participative and personalised, improving patient engagement, health outcomes and the productivity of healthcare delivery.

Alex Eavis, Chief Product Officer at EMIS, Digital, Data & Analytics, Pharmacy, considers the incredible advances that could be achieved through multidisciplinary collaboration.

The NICE Office for Digital Health, opened as part of the wider strategy to place greater focus on digital health over the next five years, launched a consultation to gather feedback on updates made to the Evidence Standards Framework (ESF) for digital health technologies (DHTs).